Health Reform Hub Issues

Issues :: Comparative Effectiveness Issues

The Emerging ObamaCare Massacre
David Hogberg

Investor's Business Daily, 10/4/10

Here’s a Post-it note for ObamaCare supporters and opponents: Over the weekend 3M (MMM), the maker of the ubiquitous sticky message pads, along with electronics, optics and more, decided to end its retirees’ access to its health care plan beginning in 2013. According to the Wall Street Journal: “health care reform has made it more difficult for employers like 3M to provide a plan that will remain competitive,” (3M said in a) memo. The White House says retiree-only plans are largely exempt from new health insurance regulations under the law. The company didn’t specify how many workers would be impacted. It currently has 23,000 U.S. retirees. Americans become eligible for the Medicare insurance program at age 65. Starting in 2015, 3M retirees too young to qualify for Medicare will receive financial support through what the company called a “health reimbursement arrangement” and won’t be able to enroll in the company’s group insurance plan. The company described that as an account retirees can use to purchase individual insurance through exchanges that the health law will create in 2014. 3M didn’t provide details on the financial contributions. Read more...

Cleveland Clinic CEO Worries Comparative Effectiveness Could Stifle Innovation
Katherine Hobson

Wall Street Journal: Health Blog, 8/20/10

The last time we looked at consumer effectiveness research — basically defined as identifying which health care services work best under which circumstances — it was consumers who were skeptical. Now it’s the CEO of the Cleveland Clinic who’s expressing concern, as the Cleveland Plain Dealer reported yesterday. In response to a question after a speech, Toby Cosgrove said he wanted to ensure that manufacturers and investors would still be willing to make financial bets on unproven devices and drugs. He used the example of a heart valve, saying it now takes two decades to bring a new valve product to market and then assess the effectiveness. Read more...

In Medicine, the Power of No
David Leonhardt
New York Times, 04/06/10

How can we learn to say no? The federal government is now starting to build the institutions that will try to reduce the soaring growth of health care costs. There will be a group to compare the effectiveness of different treatments, a so-called Medicare innovation center and a Medicare oversight board that can set payment rates. But all these groups will face the same basic problem. Deep down, Americans tend to believe that more care is better care. We recoil from efforts to restrict care...This try-anything-and-everything instinct is ingrained in our culture, and it has some big benefits. But it also has big downsides, including the side effects and risks that come with unnecessary treatment. Consider that a recent study found that 15,000 people were projected to die eventually from the radiation they received from CT scans given in just a single year — and that there was “significant overuse” of such scans. Read more...

'Comparative Effectiveness' Research Is Always Behind the Curve
Dr. Leonard A. Zwelling
Wall Street Journal, 03/16/10

President Obama's stimulus package included more than $1 billion for comparative effectiveness research (CER) on medical treatments. The bill claims the research is meant to identify "what works best for which patient under what circumstances." But if Mr. Obama's health-care plan becomes law, CER could be used by the government to make rationing and reimbursement decisions. And as an oncologist and molecular pharmacologist, I don't think CER can keep pace with advances in medicine. Read more...

The Impact of Comparative Effectiveness Research on Health and Health Care Spending 
 Tomas J. Philipson and Anirban Basu
American Enterprise Institute/National Bureau of Economic Research, 03/02/10

Public subsidization of technology assessments in general, and Comparative Effectiveness Research (CER) in particular, has received considerable attention as a tool to simultaneously improve patient health and lower the cost of health care. However, little conceptual and empirical understanding exists concerning the quantitative impact of public technology assessments such as CER. This paper analyses the impact of CER on health and medical care spending interpreting CER to shift the demand for some treatments at the expense of others. Read more...

A Simple Health-Care Fix Fizzles Out
Keith J. Winstein
Wall Street Journal, 02/11/10

It sounds like such a simple concept: Study different medical treatments and figure out which delivers the best results at the cheapest cost, giving patients the most effective care. Even before Congress took up the now-stalled health-care overhaul, it appropriated $1.1 billion to fund these studies. Both the Senate and the House included it in their versions of the bill. President Barack Obama backed it. Yet, an examination of one of the best-known examples of a comparative-effectiveness analysis shows how complicated such a seemingly straightforward idea can get. The study, known as "Courage" and published in the New England Journal of Medicine in 2007, shook the world of cardiology. It found that the most common heart surgery—a $15,000 procedure that unclogs arteries using a small scaffold or stent—usually yields no additional benefit when used with a cocktail of generic drugs in patients suffering from chronic chest pain. Read more...

Medicine Isn't Perfect, But Obamacare Is Less Perfect
Dr. David Gratzer, Manhattan Institute
The Washington Examiner, 11/25/09

The controversy over breast cancer screening shows the political and practical limitations of this one-size-fits-all approach: Medical organizations have difficulty in setting and agreeing upon clinical guidelines, and patients are apt to resent mandates from bureaucrats. Leaving health verdicts in the hands of centralized authorities is a sure way to keep making mistakes in a field where re-examination and reversal are an unavoidable reality. Read more...

Tempest In A C-Cup
Sally Satel, American Enterprise Institute
Forbes.com, 11/25/09

The mammography recommendation lands smack in the middle of a roiling health care debate. Bad timing: It makes the guideline look like a cynical move intended to save costs at the expense of lives. The recommendation also foreshadows fears of rationing, a queasy prospect indeed. In some circles, it fuels long-standing suspicions about the medical patriarchy. Read more...

Liberals and Mammography
The Wall Street Journal, 11/24/09

The flap over breast cancer screening has provided a fascinating insight into the political future of ObamaCare. Specifically, the political left supports such medical rationing even as it disavows that any such thing is happening.  Read more...

A Breast Cancer Preview 
The Wall Street Journal, 11/19/09  

A government panel's decision to toss out long-time guidelines for breast cancer screening is causing an uproar, and well it should. This episode is an all-too-instructive preview of the coming political decisions about cost-control and medical treatment that are at the heart of ObamaCare.  Read more...